Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Name | Title | Since | Age |
|---|---|---|---|
| John A. Roberts | Independent Chairman of the Board | 2025 | 67 |
| Shane J. Schaffer | Co-Founder, CEO & Director | 2025 | 51 |
| Bryan Jay Lawrence | Independent Director | 2024 | 60 |
| Jeffrey S. Ervin | Independent Director | 2024 | 48 |
| Jeff Hargroves | Independent Director | 2026 | 59 |
| Peter J. Werth | Director | 2018 | 87 |
| Ann Childress | Member of Scientific Advisory Board | - | - |
| Brian D. Barash | Member of Scientific Advisory Board | - | - |
| Andrew J. Cutler | Member of Scientific Advisory Board | - | - |
| Laurence L. Greenhill | Member of Scientific Advisory Board | - | - |
| John S. Markowitz | Member of Scientific Advisory Board | - | - |
| Dinohra Munoz-Silva | Member of Scientific Advisory Board | - | - |
| Jeffrey Newcorn | Member of Scientific Advisory Board | - | - |
| Declan Quinn | Member of Scientific Advisory Board | - | - |
| Sharon B. Wigal | Member of Scientific Advisory Board | - | - |
| Alice Mao | Member of Scientific Advisory Board | - | - |